Tripartite Motif-Containing 2, a Glutamine Metabolism-Associated Protein, Predicts Poor Patient Outcome in Triple-Negative Breast Cancer Treated with Chemotherapy

Brendah K. Masisi,Rokaya El Ansari,Lutfi Alfarsi,Ali Fakroun,Busra Erkan,Asmaa Ibrahim,Michael Toss,Ian O. Ellis,Emad A. Rakha,Andrew R. Green

DOI: https://doi.org/10.3390/cancers16111949

2024-05-22

Cancers

Abstract:Background: Breast cancer (BC) remains heterogeneous in terms of prognosis and response to treatment. Metabolic reprogramming is a critical part of oncogenesis and a potential therapeutic target. Glutaminase (GLS), which generates glutamate from glutamine, plays a role in triple-negative breast cancer (TNBC). However, targeting GLS directly may be difficult, as it is essential for normal cell function. This study aimed to determine potential targets in BC associated with glutamine metabolism and evaluate their prognostic value in BC. Methods: The iNET model was used to identify genes in BC that are associated with GLS using RNA-sequencing data. The prognostic significance of tripartite motif-containing 2 (TRIM2) mRNA was assessed in BC transcriptomic data (n = 16,575), and TRIM2 protein expression was evaluated using immunohistochemistry (n = 749) in patients with early-stage invasive breast cancer with long-term follow-up. The associations between TRIM2 expression and clinicopathological features and patient outcomes were evaluated. Results: Pathway analysis identified TRIM2 expression as an important gene co-expressed with high GLS expression in BC. High TRIM2 mRNA and TRIM2 protein expression were associated with TNBC (p < 0.01). TRIM2 was a predictor of poor distant metastasis-free survival (DMFS) in TNBC (p < 0.01), and this was independent of established prognostic factors (p < 0.05), particularly in those who received chemotherapy (p < 0.05). In addition, TRIM2 was a predictor of shorter DMFS in TNBC treated with chemotherapy (p < 0.01). Conclusions: This study provides evidence of an association between TRIM2 and poor patient outcomes in TNBC, especially those treated with chemotherapy. The molecular mechanisms and functional behaviour of TRIM2 and the functional link with GLS in BC warrant further exploration using in vitro models.

oncology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to determine whether tripartite motif - containing protein 2 (TRIM2) related to glutamine metabolism can be used as a biomarker for predicting the prognosis of patients with triple - negative breast cancer (TNBC). Specifically, the research aims to:

1. **Identify genes related to glutamine metabolism**: By using the iNET model and RNA - sequencing data, identify genes related to the glutamine - metabolizing enzyme glutaminase (GLS), especially TRIM2.

2. **Evaluate the expression level of TRIM2 in breast cancer**: By analyzing gene expression data and immunohistochemistry results, evaluate the expression level of TRIM2 in different subtypes of breast cancer, especially in triple - negative breast cancer (TNBC).

3. **Analyze the relationship between TRIM2 expression and patient prognosis**: Explore whether high TRIM2 expression is associated with poor prognosis in TNBC patients, especially in patients receiving chemotherapy.

4. **Verify the potential of TRIM2 as an independent prognostic marker**: Through multivariate survival analysis, evaluate whether TRIM2 expression can be used as an independent prognostic marker to predict the survival rate and distant metastasis risk of TNBC patients.

### Main findings

- **Association between TRIM2 and GLS**: TRIM2 is highly co - expressed with GLS in breast cancer, especially in ER - negative and TNBC subtypes.
- **Association between TRIM2 expression and TNBC prognosis**: High TRIM2 expression is significantly associated with poor prognosis in TNBC patients, especially in patients receiving chemotherapy.
- **TRIM2 as an independent prognostic marker**: Multivariate analysis shows that TRIM2 expression is an important prognostic marker independent of other known prognostic factors (such as tumor size, grade, and lymph node status).

### Conclusion

This study provides evidence that TRIM2 may be a valuable prognostic marker, especially for triple - negative breast cancer patients receiving chemotherapy. Further research is needed to explore the functional mechanism of TRIM2 and its relationship with glutamine metabolism in order to better understand its role in breast cancer progression.